(Q35760136)

10 August 2017

title

Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate (English)

1 reference

10 August 2017

1 reference

J Gratacós

1

1 reference

10 August 2017

E Casado

series ordinal

2

1 reference

10 August 2017

J Real

series ordinal

3

1 reference

10 August 2017

J C Torre-Alonso

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

19 December 2006

1 reference

Annals of the Rheumatic Diseases

10 August 2017

published in

1 reference

10 August 2017

volume

66

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

493-497

1 reference

Hip joint disease in psoriatic arthritis: risk factors and natural history

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Guideline for anti-TNF-alpha therapy in psoriatic arthritis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Current concepts and new developments in the treatment of psoriatic arthritis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Infection complications associated with the use of biologic agents

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Remission in psoriatic arthritis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856049

A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience

25 September 2018

1 reference

12 December 2020

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

12 December 2020

Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis

1 reference

12 December 2020

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions

1 reference

12 December 2020

Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid

1 reference

12 December 2020

Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death

1 reference

12 December 2020

Patterns of cytokine production in psoriatic synovium

1 reference

12 December 2020

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept

1 reference

12 December 2020

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

12 December 2020

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2006.060079

1 reference

10 August 2017

1 reference

10 August 2017

1 reference